Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis

Autor(es):Mostrar menos -

Caridha, Diana ^[1] ; Vesely, Brian ^[1] ; van Bocxlaer, Katrien ^{[2, 3]} ; Arana, Byron ^[4] ; Mowbray, Charles E. ^[4] ; Rafati, Sima ^[5] ; Uliana, Silvia ^[6] ; Reguera, Rosa ^[7] ; Kreishman-Deitrick, Mara ^[1] ; Sciotti, Richard ^[1] ; Buffet, Pierre ^[8] ; Croft, Simon L. ^[2]

Afiliação do(s) autor(es)

^[1] Walter Reed Army Inst Res, Silver Spring, MD - USA

^[2] London Sch Hyg & Trop Med, London - England

^[3] Univ York, York Biomed Res Inst, Dept Biol, York, N Yorkshire - England

^[4] Drugs Neglected Dis Initiat DNDi, Geneva - Switzerland

^[5] Inst Pasteur Inst, Dept Immunotherapy & Leishmania Vaccine Res, Tehran - Iran

^[6] Univ Sao Paulo, Biomed Sci Inst, Dept Parasitol, Sao Paulo, SP - Brazil

^[7] Univ Leon, Dept Biomed Sci, Leon - Spain

^[8] INTS, Lab Excellence GR Ex, UniteA Biol InteAgreAe Globule Rouge, Paris - France

• Tipo de documento: Artigo de Revisão
• Fonte: INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE; v. 11, n. SI, p. 106-117, DEC 2019.
• Citações Web of Science: 1

Resumo

Although there have been significant advances in the treatment of visceral leishmaniasis (VL) and several novel compounds are currently in pre-clinical and clinical development for this manifestation of leishmaniasis, there have been limited advances in drug research and development (R \& D) for cutaneous leishmaniasis (CL). Here we review the need for new treatments for CL, describe in vitro and in vivo assays, models and approaches taken over the past decade to establish a pathway for the discovery, and pre-clinical development of new drugs for CL. These recent advances include novel mouse models of infection using bioluminescent Leishmania, the introduction of PK/PD approaches to skin infection, and defined pre-clinical candidate profiles. (AU)

• Processo FAPESP: 15/09080-2 - Avaliação de candidatos a fármacos para o tratamento de leishmaniose no Brasil
• Beneficiário: Silvia Reni Bortolin Uliana
• Linha de fomento: Auxílio à Pesquisa - Regular